Startup profile · funding coverage
Aureka Biotechnologies funding, valuation and investors
AI-native TechBio building biological foundation models with closed-loop wet-lab infrastructure.
Keep track of Aureka Biotechnologies
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$100M · August 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$100M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Laguna Hills, California / Shanghai, China
Investors in latest funding
Lead: Granite Asia , Strategic investor (undisclosed)
Other: HighLight Capital , MPCi , NRL Capital
Overview
Aureka Biotechnologies is an AI-native TechBio company with bases in Laguna Hills, California and Shanghai. It develops biological foundation models (AuraIDE; open-source OpenDDE) and Lab-in-the-Loop infrastructure that couples molecular generation with high-throughput experimental validation for antibody discovery. Founded in 2023 by Dr. Weian Zhao. In August 2026 Aureka raised a $100 million Series B with Granite Asia funding the first tranche exclusively, a strategic investor leading a subsequent tranche, and participation from HighLight Capital, MPCi, and NRL Capital — nearly $200 million raised to date. The company cites strategic pharma partnerships and tens of millions in revenue over two years.
Why Aureka Biotechnologies is interesting
$100M Series B (Aug 2026, ~$200M cumulative) to scale AuraIDE — models that improve from proprietary Lab-in-the-Loop experiments, not only public protein datasets.
Product & use cases
Closed-loop AI-for-science stack: biological foundation models plus single-cell functional screening and automated experiments that feed continuous model post-training for antibody design.
- De novo antibody and biomolecular design with wet-lab feedback
- Partner with pharma on hard targets (e.g., GPCRs, dual-target antibodies)
- Benchmark and extend open biomolecular models via OpenDDE
Key facts
- Series B (Aug 2026): $100M; ~$200M cumulative (PR Newswire)
- First tranche: Granite Asia (exclusive); later tranche led by undisclosed strategic; HLC, MPCi, NRL follow-on
- Products: AuraIDE foundation model; OpenDDE open-source; Lab-in-the-Loop platforms
- Tens of millions revenue over ~2 years from discovery partnerships (company)
- No VCT /fund/ IDs yet for Granite Asia / HLC / MPCi / NRL — names press-sourced
Funding history (newest first)
Series B
2026-08 $100M- Granite Asia (lead)
- Strategic investor (undisclosed) (lead)
- HighLight Capital (participant)
- MPCi (participant)
- NRL Capital (participant)
Competitive landscape
Edge: Owns the experimental flywheel that generates proprietary functional data for foundation-model training — not only static public corpora.
Buyers increasingly want closed-loop platforms that produce developable assets, not structure scores alone. Aureka’s underwriting questions are partner concentration, geography/IP, and how fast Lab-in-the-Loop data improves real programs.
-
Chai Discovery adjacent
Structure/design-focused TechBio peer in the foundation-model wave.
-
Classic CRO + ML bolt-ons adjacent
Experiment capacity without owned biological foundation models.
-
Pharma internal AI groups adjacent
Build-vs-buy partners and competitors depending on program.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Aureka Biotechnologies's financing or category context.
FAQs about Aureka Biotechnologies
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.